New therapeutic advances in CNS injury and repair

References

• Sharma HS, Sharma A. New strategies for CNS injury and repair using stem cells, nanomedicine, neurotrophic factors and novel neuroprotective agents. Expert Rev. Neurother. 11(8), 1121–1124 (2011).
   PubMedGoogle Scholar
• Glass JD, Boulis NM, Johe K et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a Phase I trial in 12 patients. Stem Cells 30(6), 1144–1151 (2012).
   PubMed Web of Science ®Google Scholar
• Tate CC, Fonck C, McGrogan M, Case CC. Human mesenchymal stromal cells and their derivative, SB623 cells, rescue neural cells via trophic support following in vitro ischemia. Cell Transplant. 19(8), 973–984 (2010).
   PubMed Web of Science ®Google Scholar
• Fehlings MG, Theodore N, Harrop J et al. A Phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J. Neurotrauma 28(5), 787–796 (2011).
   PubMed Web of Science ®Google Scholar
• Fu QL, Liao XX, Li X et al. Soluble Nogo-66 receptor prevents synaptic dysfunction and rescues retinal ganglion cell loss in chronic glaucoma. Invest. Ophthalmol. Vis. Sci. 52(11), 8374–8380 (2011).
   PubMedGoogle Scholar
• Yang ML, Li JJ, So KF et al. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal Cord 50(2), 141–146 (2012).
   PubMed Web of Science ®Google Scholar
• Hester ME, Murtha MJ, Song S et al. Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol. Ther. 19(10), 1905–1912 (2011).
   PubMed Web of Science ®Google Scholar
• Sharma HS. New perspectives for the treatment options in spinal cord injury. Expert Opin. Pharmacother. 9(16), 2773–2800 (2008).
   PubMed Web of Science ®Google Scholar
• Raisman G, Carlstedt T, Choi D, Li Y. Clinical prospects for transplantation of OECs in the repair of brachial and lumbosacral plexus injuries: opening a door. Exp. Neurol. 229(1), 168–173 (2011).
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu L, Zhang L, Fu S, Hu Y, Wang Y et al. Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells. PLoS One 7(4), e34321 (2012).
   PubMedGoogle Scholar
• Sharma HS, Sharma A. Recent perspectives on nanoneuroprotection & nanoneurotoxicity. CNS Neurol. Disord. Drug Targets 11(1), 5–6 (2012).
   PubMedGoogle Scholar
• Tian ZR, Sharma A, Nozari A, Subramaniam R, Lundstedt T, Sharma HS. Nanowired drug delivery to enhance neuroprotection in spinal cord injury. CNS Neurol. Disord. Drug Targets 11(1), 86–95 (2012).
   PubMed Web of Science ®Google Scholar
• Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol. Disord. Drug Targets 11(1), 40–49 (2012).
   PubMed Web of Science ®Google Scholar
• Arachchige Don AS, Tsang CK, Kazdoba TM, D’Arcangelo G, Young W, Steven Zheng XF. Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. Drug Discov. Today 17(15–16), 861–868 (2012).
   PubMedGoogle Scholar
• Paule MG, Li M, Allen RR et al. Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol. Teratol. 33(2), 220–230 (2011).
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma HS. Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair. Int. Rev. Neurobiol. 102, 23–45 (2012).
   PubMed Web of Science ®Google Scholar
• Sharma HS, Sharma A. Antibodies as promising novel neuroprotective agents in the central nervous system injuries. Cent. Nerv. Syst. Agents Med. Chem. 8(3), 143–169 (2008).
   Google Scholar
• Sharma A, Muresanu DF, Mössler H, Sharma HS. Superior neuroprotective effects of cerebrolysin in nanoparticle-induced exacerbation of hyperthermia-induced brain pathology. CNS Neurol. Disord. Drug Targets 11(1), 7–25 (2012).
   PubMed Web of Science ®Google Scholar
• Sharma HS, Sharma A. Nanowired drug delivery for neuroprotection in central nervous system injuries: modulation by environmental temperature, intoxication of nanoparticles, and comorbidity factors. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(2), 184–203 (2012).
   PubMed Web of Science ®Google Scholar
• Sharma HS, Muresanu DF, Patnaik R et al. Superior neuroprotective effects of cerebrolysin in heat stroke following chronic intoxication of Cu or Ag engineered nanoparticles. A comparative study with other neuroprotective agents using biochemical and morphological approaches in the rat. J. Nanosci. Nanotechnol. 11(9), 7549–7569 (2011).
   PubMed Web of Science ®Google Scholar
• Sharma HS, Castellani RJ, Smith MA, Sharma A. The blood–brain barrier in Alzheimer’s disease: novel therapeutic targets and nanodrug delivery. Int. Rev. Neurobiol. 102, 45–88 (2012).
   Google Scholar
• Skaper S. Alzheimer’s disease and amyloid: culprit or coincidence? Int. Rev. Neurobiol. 102, 269–308 (2012).
   Google Scholar
• Johanson C, Stopa E, Baird A, Sharma H. Traumatic brain injury and recovery mechanisms: peptide modulation of periventricular neurogenic regions by the choroid plexus–CSF nexus. J. Neural Transm. 118(1), 115–133 (2011).
   PubMed Web of Science ®Google Scholar
• Hescham S, Lim LW, Jahanshahi A et al. Deep brain stimulation of the forniceal area enhances memory functions in experimental dementia: the role of stimulation parameters. Brain Stimul. doi:10.1016/j.brs.2012.01.008 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Zeef DH, Vlamings R, Lim LW et al. Motor and non-motor behaviour in experimental Huntington’s disease. Behav. Brain Res. 226(2), 435–439 (2012).
   PubMed Web of Science ®Google Scholar